Focus: Gilead commits to HIV prevention rollout for low-income countries despite funding uncertainty

Gilead Sciences intends to proceed with the rollout of its twice-yearly HIV prevention injection, lenacapavir, in low-income countries, pending FDA approval expected by June 19, despite funding uncertainties stemming from potential PEPFAR cuts under the Trump Administration. The drug, which proved nearly 100% effective in trials, could be available to at least 2 million people in 18 countries starting in 2026, with Gilead providing it at cost while generic manufacturers scale up production; however, the actual rollout scale hinges on the Global Fund's fundraising success and the level of U.S. commitment, with concerns that funding shortfalls could significantly impede HIV prevention efforts.

Analysis

Gilead Sciences has reiterated its plan to distribute its twice-yearly HIV prevention injection, lenacapavir, in low-income countries following its anticipated U.S. Food and Drug Administration (FDA) approval by June 19, despite considerable funding uncertainties stemming from the Trump Administration's reduced aid spending, notably affecting the U.S. President's Emergency Plan for AIDS Relief (PEPFAR). Lenacapavir demonstrated nearly 100% efficacy in clinical trials, and if approved by the FDA and subsequently endorsed by the WHO, Gilead intends to commence its rollout to at least 2 million people in 18 low-income countries by early 2026. This initiative involves providing lenacapavir at cost for two-to-three years while licensed generic manufacturers increase production. The success of this global health effort is, however, contingent on sustained funding from entities like PEPFAR and the Global Fund, the latter of which is seeking $18 billion for its 2027-2029 operations and has indicated a cautious, slow start to funding lenacapavir. UNAIDS has warned that a permanent discontinuation of PEPFAR-supported HIV programs could result in an additional 6.6 million new HIV infections between 2025 and 2029. While the primary financial upside for lenacapavir is expected from the U.S. market, where annual sales are projected by LSEG-compiled analyst estimates to reach $1 billion by next year with an anticipated U.S. price around $25,000 per year, the ambiguity surrounding international aid commitments casts a shadow over the full potential global impact of the drug, which is estimated to cost $100-$120 annually in low-income settings.

Key Decisions for Investors

• Investors should closely monitor the FDA's approval decision for lenacapavir, expected by June 19, as this represents a significant near-term catalyst for Gilead.
• Focus on lenacapavir's substantial U.S. market revenue potential, estimated at $1 billion annually by next year, which is likely to be the primary driver of shareholder value in the short to medium term.
• Assess the ongoing geopolitical and fiscal policy risks related to PEPFAR and Global Fund financing for the low-income country rollout, as these uncertainties could impact the broader global health narrative and potentially Gilead's long-term ESG profile, despite the initial at-cost supply commitment.